Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208012 | 0.82 | PARP1 (0.70) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3423935 | 0.82 | PARP1 (0.70) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1387263 | 0.82 | PARP1 (1.00) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL30900892 | 0.79 | PARP1 (0.70) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6931033 | 0.79 | PARP1 (0.70) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29529679 | 0.79 | PARP1 (1.00) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL215530 | 0.79 | PARP1 (1.00) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL526074 | 0.79 | PARP1 (0.70) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL21524673 | 0.79 | PARP1 (0.65) | PARP1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL11086311 | 0.79 | TNKS (0.74) | PARP1TNKS2TNKSPARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017041701-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | 浙江华海药业股份有限公司 | 2017-03-16 | — | — | WO | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2014201409-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014100767-A1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | PARP1 2477/4885KDM4E 4525/4885CYP1A2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.